GK
GKB Ophthalmics Ltd (GKB)
₹57.00
Mkt cap
₹32 Cr
P/E ratio
11.90
P/B
0.52
Div yield
0.00%
ROE
3.28%
ROCE
10.90%
EPS (TTM)
₹4.79
Book value
₹109
52W range
14–92
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, GKB Ophthalmics Ltd is engaged in the manufacture and sale of ophthalmic lenses made up of Glass and Plastic. [1]
NSE GKBBSE 533212
Health check
Mixed
ValuationCheap
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−37.70% from high₹57
₹14+300.00% from low₹92
Current
₹57.00
Prev close
₹58.64
Day
−2.80%
Price performance
1D
−2.68%
1W
−11.26%
1M
−2.63%
3M
−9.46%
6M
+33.50%
1Y
+271.79%
YTD
−12.31%
Financials
Revenue, profit & margin
P/E ratio
11.9×
GKB is 74% below the sector median of 45.7×
GKB11.9×
Sector median45.7×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.40 | 24.04 | 21.56 | 26.02 | 26.14 | 25.80 | 31.02 | 32.31 | 30.17 | 56.79 | 29.79 | 33.04 | 32.75 | |
| YoY Sales growth | +9.91% | +25.80% | +8.02% | +16.89% | +28.14% | +7.32% | +43.88% | +24.17% | +15.42% | +120.12% | -3.97% | +2.26% | +8.55% | |
| Expenses | 20.69 | 24.66 | 21.56 | 24.98 | 26.20 | 26.74 | 33.88 | 31.51 | 27.15 | 55.13 | 26.71 | 30.41 | 30.22 | |
| Operating Profit | -0.29 | -0.62 | 0.00 | 1.04 | -0.06 | -0.94 | -2.86 | 0.80 | 3.02 | 1.66 | 3.08 | 2.63 | 2.53 | |
| OPM % | -1.42% | -2.58% | 0.00% | 4.00% | -0.23% | -3.64% | -9.22% | 2.48% | 10.01% | 2.92% | 10.34% | 7.96% | 7.73% | |
| Other Income | 0.31 | 0.35 | 0.60 | 0.28 | 0.28 | 0.48 | 0.35 | 0.21 | 0.37 | 0.57 | -0.68 | 0.73 | 0.62 | |
| Interest | 0.46 | 0.44 | 0.57 | 0.55 | 0.55 | 0.63 | 0.63 | 0.77 | 0.66 | 0.73 | 0.52 | 0.51 | 0.43 | |
| Depreciation | 0.73 | 0.73 | 0.72 | 0.76 | 0.77 | 0.77 | 0.80 | 0.80 | 0.82 | 0.82 | 0.80 | 0.80 | 0.81 | |
| Profit before tax | -1.17 | -1.44 | -0.69 | 0.01 | -1.10 | -1.86 | -3.94 | -0.56 | 1.91 | 0.68 | 1.08 | 2.05 | 1.91 | |
| Tax % | 0.00% | 0.00% | 30.43% | 600.00% | 5.45% | 2.69% | 4.82% | 14.29% | 3.66% | -4.41% | -3.70% | 9.76% | 36.13% | |
| Net Profit | -1.19 | -1.44 | -0.89 | 0.11 | -1.15 | -1.91 | -4.13 | -0.64 | 1.84 | 0.70 | 1.12 | 1.85 | 1.22 | |
| EPS in Rs | -2.32 | -2.48 | -1.81 | -0.50 | -2.42 | -4.03 | -7.04 | -2.02 | 3.17 | 0.87 | 0.38 | 2.00 | 1.31 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.15%Promoter
Promoters51.15%
FIIs1.79%
Public47.07%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | ₹1,493.20 | 237.31 | 17,208 | 0.00% | 8 | −86.23% | 259 | −55.36% | 18.48% |
| Poly Medicure | ₹1,681.20 | 53.91 | 17,041 | 0.21% | 95 | −4.31% | 581 | +30.79% | 12.50% |
| Sahajanand Medi | ₹533.95 | 75.58 | 5,427 | 0.00% | 26 | +32.12% | 373 | +24.69% | 11.35% |
| Fischer Medical | ₹24.87 | 70.98 | 1,738 | 0.20% | 4 | −22.02% | 82 | +249.49% | 11.45% |
| Tarsons Products | ₹315.45 | 205.18 | 1,678 | 0.00% | 0 | −110.24% | 124 | +20.83% | 4.59% |
| Q-Line Biotech | ₹488.30 | 20.81 | 1,139 | 0.00% | 20 | −8.07% | 152 | +5.83% | 22.45% |
| Laxmi Dental | ₹204.00 | 30.94 | 1,123 | 0.00% | 10 | +17.58% | 80 | +10.03% | 15.05% |
| GKB Ophthalmics | ₹64.31 | 11.88 | 32 | 0.00% | 1 | −58.75% | 33 | +8.55% | 10.90% |
| Median: 18 Co. | ₹311.00 | 45.73 | 756 | 0.00% | 5 | −0.05% | 81 | +19.56% | 15.05% |
Filings
Annual reports15
Credit ratings6
Announcements5
Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026. 12 NovBoard Meeting Outcome for Outcome Of The Board Meeting Held On November 12, 2026. 12 Nov - On Nov 12, 2026, board approved Q2 FY26 results, debonded Unit II EOU, and planned sub-lease.Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 29 Oct - Board meets November 12, 2026 to approve Q2 and half-year unaudited results; trading window reopens later.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Oct - Please find herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.Closure of Trading Window 28 Sep
